Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma.
Herbst C, Rehan FA, Skoetz N, Bohlius J, Brillant C, Schulz H, Monsef I, Specht L, Engert A. Herbst C, et al. Among authors: brillant c. Cochrane Database Syst Rev. 2011 Feb 16;(2):CD007110. doi: 10.1002/14651858.CD007110.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2017 Apr 27;4:CD007110. doi: 10.1002/14651858.CD007110.pub3 PMID: 21328291 Free article. Updated. Review.
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Bauer K, et al. Among authors: brillant c. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD007941. doi: 10.1002/14651858.CD007941.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2017 May 25;5:CD007941. doi: 10.1002/14651858.CD007941.pub3 PMID: 21833963 Updated. Review.
Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
Nogová L, Reineke T, Eich HT, Josting A, Müller-Hermelink HK, Wingbermühle K, Brillant C, Gossmann A, Oertel J, Bollen MV, Müller RP, Diehl V, Engert A. Nogová L, et al. Among authors: brillant c. Ann Oncol. 2005 Oct;16(10):1683-7. doi: 10.1093/annonc/mdi323. Epub 2005 Aug 10. Ann Oncol. 2005. PMID: 16093276 Free article.
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials.
Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Fermé C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J. Franklin J, et al. Among authors: brillant c. Ann Oncol. 2006 Dec;17(12):1749-60. doi: 10.1093/annonc/mdl302. Epub 2006 Sep 19. Ann Oncol. 2006. PMID: 16984979 Free article.
Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V. Engert A, et al. Among authors: brillant c. J Clin Oncol. 2007 Aug 10;25(23):3495-502. doi: 10.1200/JCO.2006.07.0482. Epub 2007 Jul 2. J Clin Oncol. 2007. PMID: 17606976 Clinical Trial.
22 results